Hereditary Cancer Surveillance Using Cell-free DNA Sequencing
CME and CMLE credits are not available for this webinar.
Description:
This presentation will discuss findings from multiple different types of hereditary cancer syndromes utilizing a combination of mutational, fragmentomic, and epigenetic approaches to cell-free DNA analysis. It will also introduce data sharing and analytic strategies to increase the sensitivity and impact of these techniques.
Carriers of hereditary cancer syndromes are at heightened risk for malignancy and therefore undergo annual clinical screening for a host of cancers. As cancers are now well-known to shed cell-free DNA into the blood stream, the CHARM consortium (Cell-free DNA in Hereditary and High-risk Malignancies, www.charmconsortium.ca) was founded to assess whether regular genome and methylome profiling of blood plasma can detect the earliest cancers in this population. This presentation will examine this initiative.
Learning Objectives:
- Identify some of the challenges with the collection, generation, and interpretation of liquid biopsy data in clinical studies
- Compare different biological aspects of cell-free DNA and associated technologies to detect early cancer
- Examine initiatives in hereditary cancer to assess the use of cell-free DNA sequencing technologies for cancer screening
 |
 |
|---|---|
| Speaker: Trevor Pugh, PhD, FACMG Princess Margaret Cancer Centre Ontario Institute for Cancer Research |
Moderator: Lynette Scholl, MD Harvard-Brigham and Women's Hospital |
Continuing Education Credit Information
CME and CMLE credits are not available for this webinar.
Recording Date: February 2, 2023
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation
